P53 Vs NF-κB: the Role of Nuclear Factor-kappa B in the Regulation of P53 Activity and Vice Versa

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2020 Apr 24

PMID 32322927

Citations 28

Authors

Giovanna Carra

Marcello Francesco Lingua

Beatrice Maffeo

Riccardo Taulli

Alessandro Morotti

Affiliations

Soon will be listed here.

Abstract

The onco-suppressor p53 is a transcription factor that regulates a wide spectrum of genes involved in various cellular functions including apoptosis, cell cycle arrest, senescence, autophagy, DNA repair and angiogenesis. p53 and NF-κB generally have opposing effects in cancer cells. While p53 activity is associated with apoptosis induction, the stimulation of NF-κB has been demonstrated to promote resistance to programmed cell death. Although the transcription factor NF-κB family is considered as the master regulator of cancer development and maintenance, it has been mainly studied in relation to its ability to regulate p53. This has revealed the importance of the crosstalk between NF-κB, p53 and other crucial cell signaling pathways. This review analyzes the various mechanisms by which NF-κB regulates the activity of p53 and the role of p53 on NF-κB activity.

Citing Articles

Exploring the role of oral bacteria in oral cancer: a narrative review.

Mivehchi H, Eskandari-Yaghbastlo A, Pour Bahrami P, Elhami A, Faghihinia F, Nejati S Discov Oncol. 2025; 16(1):242.

PMID: 40009328 PMC: 11865422. DOI: 10.1007/s12672-025-01998-2.

"Friends or foes": a new perspective of tumour metabolic transcriptional modification.

Shi T, Geng Q, Wang Z, Wen C, Xu J, Jiao Y Cell Death Dis. 2025; 16(1):106.

PMID: 39962057 PMC: 11833121. DOI: 10.1038/s41419-025-07429-y.

Exploring the various functions of PHD finger protein 20: beyond the unknown.

Juang U, Gwon S, Jung W, Nguyen H, Huang Q, Lee S Toxicol Res. 2025; 41(1):1-11.

PMID: 39802118 PMC: 11717773. DOI: 10.1007/s43188-024-00265-w.

Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck Cancer.

de Bakker T, Maes A, Dragan T, Martinive P, Penninckx S, Van Gestel D Cells. 2025; 14(1.

PMID: 39791719 PMC: 11719474. DOI: 10.3390/cells14010018.

Exploring Piperine: Unleashing the multifaceted potential of a phytochemical in cancer therapy.

Tripathi D, Gupta T, Pandey P Mol Biol Rep. 2024; 51(1):1050.

PMID: 39395120 DOI: 10.1007/s11033-024-09978-5.

References

Heyne K, Winter C, Gerten F, Schmidt C, Roemer K . A novel mechanism of crosstalk between the p53 and NFκB pathways: MDM2 binds and inhibits p65RelA. Cell Cycle. 2013; 12(15):2479-92. PMC: 3841326. DOI: 10.4161/cc.25495. View

Hellin A, Calmant P, Gielen J, Bours V, Merville M . Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene. 1998; 16(9):1187-95. DOI: 10.1038/sj.onc.1201638. View

Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I . p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell. 2002; 1(5):493-503. DOI: 10.1016/s1535-6108(02)00068-5. View

Lozano G, Levine A . Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog. 1991; 4(1):3-9. DOI: 10.1002/mc.2940040103. View

Johnson R, Witzel I, Perkins N . p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-κB. Cancer Res. 2011; 71(16):5588-97. PMC: 3379538. DOI: 10.1158/0008-5472.CAN-10-4252. View

Pitolli C, Wang Y, Candi E, Shi Y, Melino G, Amelio I . p53-Mediated Tumor Suppression: DNA-Damage Response and Alternative Mechanisms. Cancers (Basel). 2019; 11(12). PMC: 6966539. DOI: 10.3390/cancers11121983. View

Gudkov A, Komarova E . p53 and the Carcinogenicity of Chronic Inflammation. Cold Spring Harb Perspect Med. 2016; 6(11). PMC: 5088512. DOI: 10.1101/cshperspect.a026161. View

Bjorkman M, Ostling P, Harma V, Virtanen J, Mpindi J, Rantala J . Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene. 2011; 31(29):3444-56. DOI: 10.1038/onc.2011.512. View

Huber M, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H . NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004; 114(4):569-81. PMC: 503772. DOI: 10.1172/JCI21358. View

10.

Deffie A, Wu H, Reinke V, Lozano G . The tumor suppressor p53 regulates its own transcription. Mol Cell Biol. 1993; 13(6):3415-23. PMC: 359810. DOI: 10.1128/mcb.13.6.3415-3423.1993. View

11.

Ravi R, Mookerjee B, van Hensbergen Y, Bedi G, Giordano A, El-Deiry W . p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res. 1998; 58(20):4531-6. View

12.

Ghose J, Bhattacharyya N . Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells. RNA Biol. 2015; 12(4):457-77. PMC: 4615384. DOI: 10.1080/15476286.2015.1014288. View

13.

Carra G, Crivellaro S, Taulli R, Guerrasio A, Saglio G, Morotti A . Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex. Int J Mol Sci. 2016; 17(12). PMC: 5187797. DOI: 10.3390/ijms17121997. View

14.

Sun Q, Hu B, Fu P, Tang W, Zhang X, Zhan H . Long non-coding RNA 00607 as a tumor suppressor by modulating NF-κB p65/p53 signaling axis in hepatocellular carcinoma. Carcinogenesis. 2018; 39(12):1438-1446. DOI: 10.1093/carcin/bgy113. View

15.

Murphy S, Suzuki K, Downes M, Welch G, De Jesus P, Miraglia L . Tumor suppressor protein (p)53, is a regulator of NF-kappaB repression by the glucocorticoid receptor. Proc Natl Acad Sci U S A. 2011; 108(41):17117-22. PMC: 3193198. DOI: 10.1073/pnas.1114420108. View

16.

Ak P, Levine A . p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J. 2010; 24(10):3643-52. DOI: 10.1096/fj.10-160549. View

17.

Zhang Y, Weinberg R . Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018; 12(4):361-373. PMC: 6186394. DOI: 10.1007/s11684-018-0656-6. View

18.

Tergaonkar V, Perkins N . p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Mol Cell. 2007; 26(2):158-9. DOI: 10.1016/j.molcel.2007.04.006. View

19.

Jonak K, Kurpas M, Szoltysek K, Janus P, Abramowicz A, Puszynski K . A novel mathematical model of ATM/p53/NF- κB pathways points to the importance of the DDR switch-off mechanisms. BMC Syst Biol. 2016; 10(1):75. PMC: 4986247. DOI: 10.1186/s12918-016-0293-0. View

20.

Kwon M, Jang H, Kim E, Roh J . Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions. Cell Cycle. 2016; 15(22):3105-3114. PMC: 5134701. DOI: 10.1080/15384101.2016.1235104. View